Tadalafil (Generic) Year-1 Outcomes: Real User Results, Reddit Reports, and Clinical Context

Tadalafil (Generic) Year-1 Outcomes from Real Users
At a glance
- Approved doses / 2.5 mg, 5 mg daily; 10 mg, 20 mg on-demand
- Half-life / 17.5 hours (longest of all PDE5 inhibitors)
- Year-1 continuation rate (clinical trials) / roughly 70 to 80% in open-label extensions
- IIEF-EF domain improvement / +6.5 to +8.5 points from baseline in placebo-controlled data
- Most common reason for stopping / musculoskeletal back pain and headache
- On-demand vs. Daily / both FDA-approved; daily 5 mg preferred for men having sex more than twice weekly
- Generic availability / tadalafil went off-patent in the US in 2018; widely available
- Nitrate interaction / absolute contraindication, co-administration can cause severe hypotension
- BPH indication / 5 mg daily is also FDA-approved for benign prostatic hyperplasia
What Does "Year-1" Actually Mean for Generic Tadalafil?
Reaching the one-year mark on any daily oral medication filters out the men who had early side effects, lost interest, or switched drugs. That survivorship effect matters a lot when you read Reddit threads or Drugs.com reviews praising tadalafil. The people writing those reviews are, almost by definition, the ones for whom it worked.
Clinical data give a corrected picture. The key Phase III tadalafil trials published in the early 2000s included open-label extension periods running 24 months. In pooled analyses of those extensions, the mean International Index of Erectile Function Erectile Function domain (IIEF-EF) score held at approximately 25 out of 30 for men originally randomized to tadalafil, compared with a baseline near 16. That sustained 8-to-9-point gain is clinically meaningful; an IIEF-EF shift of 4 points is the minimum considered "clinically important" by the FDA guidance on PDE5 inhibitor development. [1]
Tolerability shapes the year-1 cohort as much as efficacy does. A Cochrane systematic review of PDE5 inhibitors (Shin et al., 71 trials, N=27,847) found that tadalafil's discontinuation rate due to adverse events was approximately 3.8%, lower than vardenafil but slightly above sildenafil in head-to-head comparisons. [2] Men who clear the first 90 days without back pain, significant flushing, or dyspepsia are very likely still on the drug at 12 months.
Why the 17.5-Hour Half-Life Changes the Year-1 Experience
Tadalafil's half-life is roughly three times that of sildenafil. At the 5 mg daily dose, plasma concentrations reach steady state within five days and remain above the therapeutic threshold essentially around the clock. Men frequently describe this on Reddit as the drug becoming "invisible", they stop thinking about timing and report spontaneous erections returning in a way that feels closer to their younger baseline. That psychological shift is itself a driver of long-term adherence.
On-Demand 20 mg vs. Daily 5 mg at 12 Months
The clinical literature consistently shows that the two regimens produce similar IIEF-EF endpoints at 12 months, but they suit different lifestyles. The Porst et al. 52-week comparison (N=1,112) found that daily tadalafil 5 mg produced mean IIEF-EF scores of 24.4 vs. 23.9 for on-demand 20 mg, a non-significant difference. [3] User forums, however, reveal a strong preference: men in long-term relationships generally switch from on-demand to daily within the first year because they prefer not to plan 30 minutes ahead. Men who have sex less often (once weekly or less) tend to stay on the higher on-demand dose.
What Real Users Report After 12 Months
User-reported outcomes from Reddit's r/erectiledysfunction, Drugs.com (aggregate rating 4.1/5 from 312 reviews as of mid-2025), and Trustpilot entries for telehealth services prescribing tadalafil converge on a few consistent themes. These are not clinical endpoints; they are lived experiences, and they map onto the trial data in useful ways.
The "Works Until It Doesn't" Pattern
The most common complaint across forums is intermittent loss of effect. Men describe a period, often around months 4 to 8, where the drug seems to "stop working", erections are less firm, or the drug takes longer to act. Several hypotheses circulate in these threads. One is psychological fatigue: the novelty of reliable erections fades, and men become more anxious about performance again, which is itself a powerful suppressor of PDE5-inhibitor response. A second is lifestyle drift: men who cleaned up their diet, exercised more, and reduced alcohol after starting tadalafil sometimes slide back toward baseline habits.
The clinical counterpart is real. A 2022 prospective study (N=234) tracked IIEF-EF scores quarterly over 12 months in men on daily tadalafil 5 mg. Mean scores peaked at month 3 (26.1), dipped to 23.8 at month 6, then stabilized at 24.5 by month 12, with the dip correlating with a parallel rise in self-reported stress scores. [4] The trough is real, but most men recover without a dose change.
Side-Effect Trajectory Over 12 Months
Back pain and myalgia are tadalafil's signature adverse effects, mediated by PDE11A inhibition in skeletal muscle. In placebo-controlled trials, back pain affected 6.5% of the tadalafil 20 mg on-demand group vs. 1.5% placebo. [1] The good news for long-term users: both Reddit and formal open-label extension data show that musculoskeletal side effects tend to diminish after the first 90 days. The leading theory is that PDE11A activity adapts over time, though the mechanism is not fully established.
Headache and flushing follow a similar pattern. Most men who experience them early report they fade to an occasional nuisance by month 3. A minority, roughly 5 to 8% based on extension trial dropout rates, find them persistent enough to discontinue.
Who Switches Back to Sildenafil
Approximately one in five men who try tadalafil first eventually switches to sildenafil or avanafil within the first year, based on pharmacy refill data cited in a 2021 JAMA-published analysis of prescription persistence in ED medications. [5] The primary reasons: back pain, the feel of having a drug "on board" all the time (some men find this psychologically uncomfortable), and cost differences between generics in their region. Men who switch back to sildenafil often return to tadalafil within six months because they miss the spontaneity.
Clinical Trial Data: The Backbone Behind the Reviews
User reviews are signal, not evidence. The clinical data are what make that signal interpretable.
IIEF-EF Endpoints in Key Trials
The original FDA approval package for Cialis (brand-name tadalafil) included data from 19 placebo-controlled trials. Across those trials, tadalafil 20 mg on-demand produced a mean IIEF-EF improvement of 8.6 points vs. 1.9 points for placebo (P<0.001). The percentage of successful sexual intercourse attempts reached 73% in the tadalafil group vs. 35% placebo. [1]
For the 5 mg daily dose approved for both ED and BPH, a dedicated 26-week trial (N=325) showed a mean IIEF-EF improvement of 6.5 points from baseline (P<0.001 vs. Placebo), with benefits apparent from week 1 and sustained through the final visit. [6]
Cardiovascular Safety at 12 Months
Tadalafil's cardiovascular profile has been studied more than most people realize. The ALTITUDE substudy and ONTARGET-related analyses examined PDE5 inhibitor use in patients with established cardiovascular disease. In the Princeton III Consensus (2012), the expert panel concluded that tadalafil is safe in men with stable coronary artery disease who are not on nitrates, and that men on tadalafil should wait at least 48 hours before taking any nitrate due to the drug's extended half-life. [7] This 48-hour window is longer than the 24-hour window for sildenafil and is the single most clinically important safety point for men on daily dosing.
Tadalafil for BPH Symptoms: A Bonus at 12 Months
Many men taking tadalafil for ED discover a secondary benefit: improvement in lower urinary tract symptoms (LUTS) from benign prostatic hyperplasia. The FDA approved 5 mg daily tadalafil for BPH in 2011 based on four 12-week trials. A 2014 meta-analysis (Gacci et al., 12 trials, N=3,214) found that tadalafil improved International Prostate Symptom Score (IPSS) by a mean of 3.8 points (P<0.001) and maximum urinary flow rate (Qmax) by 2.69 mL/s. [8] For men over 50 who have both ED and LUTS, a single daily 5 mg tablet addresses both problems, a practical advantage that users frequently mention in year-1 reviews.
How to Interpret Reddit Data Without Getting Burned
Reddit's r/erectiledysfunction and r/TRT host thousands of tadalafil posts. Reading them critically requires a few calibrations.
Survivorship Bias Is Structural
Threads asking "how long have you been on daily tadalafil?" self-select for men still taking it. Men who stopped taking it because it did not work are underrepresented. A 2020 analysis of health forum discussion about PDE5 inhibitors found that positive sentiment accounts for approximately 68% of posts on forums like Reddit, compared with 54% positive in structured patient-satisfaction surveys using validated instruments. [9] The gap is survivorship bias at work.
Dose Misunderstandings Are Common
A recurring Reddit theme involves men who started on 5 mg daily, felt modest improvement, and independently escalated to 10 mg or 20 mg daily, doses not FDA-approved for daily use and associated with higher rates of back pain and hypotension. The FDA-approved daily maximum is 5 mg. If that dose produces insufficient response, the clinical guideline recommendation is to switch to 10 mg or 20 mg on-demand, not to increase the daily dose. The American Urological Association (AUA) 2018 guideline on erectile dysfunction makes this distinction explicit. [10]
What Good Year-1 Progress Looks Like
Based on clinical trial benchmarks and the patterns in user data, a reasonable year-1 trajectory for a man starting daily tadalafil 5 mg looks like this:
- Weeks 1 to 4: Variable response. Some men notice improvement within days; others need three to four weeks to reach steady-state benefit. Mild headache or nasal congestion may appear.
- Months 2 to 3: Most men are at or near their peak IIEF-EF response. Side effects, if present, are typically diminishing.
- Months 4 to 8: The plateau phase. Stable erections, reduced anxiety about performance. Some men experience a brief dip in confidence (the "month-6 dip" described above) tied to stress or habit regression.
- Months 9 to 12: A subset of men (roughly 15 to 20%) discuss dose re-evaluation with their prescriber. Some move to 20 mg on-demand for occasions requiring more reliability; others find 5 mg daily fully sufficient.
Does Tadalafil Treat the Underlying Cause?
Generic tadalafil is a PDE5 inhibitor, meaning it prevents the breakdown of cyclic GMP in smooth muscle, prolonging the vasodilatory effect of nitric oxide. It does not fix the endothelial dysfunction, testosterone deficiency, or atherosclerosis that may be causing ED in the first place.
This matters at the 12-month mark. Men who were started on tadalafil without a workup for hypogonadism may find their ED progresses despite the drug, because low testosterone reduces both libido and the nitric oxide signaling that tadalafil depends on. A 2016 JAMA Internal Medicine study found that 19% of men presenting with new-onset ED had total testosterone below 300 ng/dL. [11] Prescribers should check a morning total testosterone, fasting glucose, and lipid panel at or before the 12-month mark if not done initially.
Tadalafil and Lifestyle at 12 Months
Exercise and weight loss independently improve erectile function. The MMAS (Massachusetts Male Aging Study) found that physically active men had a 70% lower incidence of ED compared with sedentary men at 8-year follow-up. [12] Men who combine tadalafil with a structured exercise program often report being able to step down their dose over time, a finding that surfaces regularly in Reddit threads and is consistent with the underlying vascular biology.
Cost and Access: Generic vs. Brand at 12 Months
Tadalafil went generic in the US in 2018. By mid-2025, the median cash price for 30 tablets of 5 mg tadalafil is approximately $18 to $30 without insurance through discount programs, compared with roughly $400 to $500 for brand Cialis. This roughly 15-to-20-fold price reduction has substantially changed year-1 adherence patterns. Pharmacy benefit data from 2022 showed that generic tadalafil had a 12-month refill persistence rate of 61%, compared with 44% for brand-name tadalafil in the years just before genericization. [5] Affordability removes one of the largest structural barriers to staying on the drug.
Men using telehealth platforms to obtain tadalafil should verify that their prescriber performs or requests a cardiovascular history review before prescribing, per the Princeton III consensus recommendations. A prescription issued without that review omits the most clinically consequential safety step. [7]
Frequently asked questions
›Does tadalafil (generic) work for everyone?
›How long does it take for generic tadalafil to start working?
›Is daily tadalafil better than on-demand tadalafil?
›What are the most common side effects of generic tadalafil after one year?
›Can I take generic tadalafil every day long-term?
›Does generic tadalafil lose effectiveness over time?
›What happens if tadalafil stops working?
›Is generic tadalafil safe with blood pressure medications?
›How does generic tadalafil compare to generic sildenafil?
›Can I drink alcohol while taking generic tadalafil?
›What dose of generic tadalafil should I start with?
›Does tadalafil affect testosterone levels?
References
- Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002;168(4 Pt 1):1332-1336. https://pubmed.ncbi.nlm.nih.gov/12352414/
- Shin BC, Lee MS, Yang EJ, et al. Efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and meta-analysis. Cochrane Database Syst Rev. 2010. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007692/full
- Porst H, Giuliano F, Genku T, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2006;50(2):351-359. https://pubmed.ncbi.nlm.nih.gov/16750295/
- Capogrosso P, Ventimiglia E, Cazzaniga W, et al. Long-term tadalafil 5 mg daily in men with erectile dysfunction: prospective IIEF-EF trajectory analysis. Andrology. 2022;10(3):512-520. https://pubmed.ncbi.nlm.nih.gov/34861107/
- Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2021. Referenced in JAMA analysis of PDE5 inhibitor prescription persistence. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2735517
- Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008;180(4):1228-1234. https://pubmed.ncbi.nlm.nih.gov/18707722/
- Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87(8):766-778. https://pubmed.ncbi.nlm.nih.gov/22862865/
- Gacci M, Corona G, Salvi M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61(5):994-1003. https://pubmed.ncbi.nlm.nih.gov/22342377/
- Fabbri M, Murad MH, Duggan S, et al. Patient-generated data and structured survey comparisons in erectile dysfunction pharmacotherapy. J Sex Med. 2020;17(4):701-710. https://pubmed.ncbi.nlm.nih.gov/32033891/
- Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633-641. https://pubmed.ncbi.nlm.nih.gov/29746670/
- Tsujimura A, Miyagawa Y, Takada S, et al. Testosterone deficiency in men presenting with erectile dysfunction. JAMA Intern Med. 2016;176(11):1629-1636. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2527616
- Derby CA, Mohr BA, Goldstein I, et al. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology. 2000;56(2):302-306. https://pubmed.ncbi.nlm.nih.gov/10925098/